Loading
NASDAQHealthcareMedical - Instruments & Supplies
Latest quote
$2.83
+$0.15 · +5.60%
Femasys Inc., a biomedical company established in 2004 and based in Suwanee, Georgia, primarily targets the women's healthcare market within the United States. The firm's innovative product line includes permanent contraceptive solutions such as FemBloc and FemChec, alongside FemaSeed, which is an artificial insemination offering. For diagnostic purposes, Femasys provides FemCerv, a biopsy device utilized for endocervical curettage, and FemEMB, a product candidate intended for endometrial sampling to assist in the detection of uterine cancer. Additionally, the company markets its FemVue saline-air device across various international regions, including the U.S., Europe, Canada, and Japan. Its infertility-related products are supplied to obstetrician-gynecologists, other allied healthcare professionals, women's healthcare provider organizations, and reproductive endocrinologists. The company also offers a range of non-surgical product technologies.
Previous close
$2.83
+$0.15 · +5.60%
After-hours
$2.83
$0.00 · 0.00%
Sep 9, 7:30 PM ET
Regular session · ET · Market data may be delayed.
Femasys Inc., a biomedical company established in 2004 and based in Suwanee, Georgia, primarily targets the women's healthcare market within the United States. The firm's innovative product line includes permanent contraceptive solutions such as FemBloc and FemChec, alongside FemaSeed, which is an artificial insemination offering. For diagnostic purposes, Femasys provides FemCerv, a biopsy device utilized for endocervical curettage, and FemEMB, a product candidate intended for endometrial sampling to assist in the detection of uterine cancer. Additionally, the company markets its FemVue saline-air device across various international regions, including the U.S., Europe, Canada, and Japan. Its infertility-related products are supplied to obstetrician-gynecologists, other allied healthcare professionals, women's healthcare provider organizations, and reproductive endocrinologists. The company also offers a range of non-surgical product technologies.
Day range
Current $2.83
52-week range
Current $2.83
Regular session · ET · Market data may be delayed.
GoAI Score
Hold
Valuation
66
Undervalued
Sentiment
49
Mixed
Risk
66
High Risk
Momentum
17
Strong Down
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
Femasys Inc., a biomedical company established in 2004 and based in Suwanee, Georgia, primarily targets the women's healthcare market within the United States. The firm's innovative product line includes permanent contraceptive solutions such as FemBloc and FemChec, alongside FemaSeed, which is an artificial insemination offering. For diagnostic purposes, Femasys provides FemCerv, a biopsy device utilized for endocervical curettage, and FemEMB, a product candidate intended for endometrial sampling to assist in the detection of uterine cancer. Additionally, the company markets its FemVue saline-air device across various international regions, including the U.S., Europe, Canada, and Japan. Its infertility-related products are supplied to obstetrician-gynecologists, other allied healthcare professionals, women's healthcare provider organizations, and reproductive endocrinologists. The company also offers a range of non-surgical product technologies.
Day range
Current $2.83
52-week range
Current $2.83
Profitability as a percentage of reported revenue.
Revenue
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 2.29M USD | 1.63M USD | 1.07M USD | 1.21M USD | 1.18M USD |
| Cost of goods sold | 872.4K USD | 544.9K USD | 380.07K USD | 441.94K USD | 370.38K USD |
| Gross profit | 1.42M USD | 1.08M USD | 691.9K USD | 764.28K USD | 809.31K USD |
| Research and development | 7.58M USD | 8.22M USD | 7.21M USD | 5.81M USD | 4.08M USD |
| Selling, general, and administrative | 11.09M USD | 10.36M USD | 7.51M USD | 5.99M USD | 4.47M USD |
| Operating expenses | 19.01M USD | 18.87M USD | 15.2M USD | 12.36M USD | 9.15M USD |
| Interest income | 101.76K USD | 582.35K USD | 431.02K USD | 228.16K USD | 3.77K USD |
| Interest expense | 1.89M USD | 1.6M USD | 165.39K USD | 13.46K USD | 19.23K USD |
| Depreciation and amortization | 850.46K USD | 872K USD | 907.99K USD | 889.14K USD | 964.29K USD |
| Operating income | −17.59M USD | −17.79M USD | −14.51M USD | −11.6M USD | −8.34M USD |
| Net income | −18.63M USD | −18.82M USD | −14.25M USD | −11.39M USD | −7.54M USD |
Company facts updated Sep 10, 2026.
Recent quarterly results
Recent quarterly results
| Action | Effective date | Details | Record date | Payment date |
|---|---|---|---|---|
Stock split | Jun 8, 2026 | 1:20 | — | — |
Effective Jun 8, 2026
1:20
Funds reporting this stock among their holdings, ordered by reported position size.
AI-generated and delayed market data for informational and educational purposes only. Not investment advice.
